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Purpose: To compare suprapubic open prostatectomy (SOP) and a novel SOP with transurethral
adjustment of residual adenoma and bleeding (TURARAB) for large sized prostates.
Methods: Between March 2010 and March 2014, 49 patients with symptomatic BPH (>100 g) were
scheduled for SOP or SOP with TURARAB. The patients were subdivided into two groups. In Group I, each
patient underwent SOP. In Group II, each patient underwent SOP with TURARAB. Additional transurethral
resection of residual adenoma and bleeding control were done through the urethra after enucleation of
the prostate adenoma by SOP. Prior to intervention, all patients were analyzed by preoperative complete
blood count, blood chemistry, prostate speciﬁc antigen, International Prostate Symptom Scores, and
transrectal ultrasound of the prostate and uroﬂowmetry. SOP was performed by a suprapubic trans-
vesical approach via a midline incision. The bladder neck mucosa was circularly incised to expose the
prostate adenoma, and the plane between the adenoma and surgical capsule was developed by ﬁnger
dissection. In addition, in Group II TURARAB was performed using Urosol. Postoperative outcome data
were compared in the 1st month and 3rd month.
Results: There were no statistically signiﬁcant differences in baseline characteristics between the two
groups. Group I required a longer operative time than Group II. Blood transfusion during the operation
was unnecessary due to the short amount of time available to control arterial bleeding in the prostatic
fossa leading to a marked decrease in perioperative bleeding in Group II. Postoperative voiding function
improved signiﬁcantly in both groups.
Conclusions: Even for large prostate glands, our novel procedure appears to be an effective and safe
operation to reduce operation time, bleeding, and complications.
© 2015 Published by Elsevier B.V. on behalf of Prostate International. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Of all modalities for the treatment of bladder outlet obstruction
(BOO) caused by benign prostatic hyperplasia (BPH), open prosta-
tectomy (OP) provides the highest probability of symptomatic
improvement and the lowest failure rate.1 It is the true gold stan-
dard of BPH surgery with respect to outcome and durability. How-
ever, open surgery also has the highest perioperative morbidity. The
2003 American Urological Association guideline on the manage-
ment of BPH reports a blood transfusion rate as high as 27%.2honbuk National University
f Korea.
ier B.V. on behalf of Prostate InteThe disadvantages of OP include the need for long operating
times and hospitalization. There may also be an increased potential
for perioperative hemorrhage.
To reduce these disadvantages of OP and trim the remnant tis-
sue after OP, we designed a novel suprapubic open prostatectomy
(SOP) with transurethral adjustment of residual adenoma and
bleeding (TURARAB) for larger sized prostates.2. Methods
2.1. Patients
Between March 2010 and April 2012, 29 patients with symp-
tomatic BPH (>100 g) were scheduled for SOP, and 20 patients with
symptomatic BPH (>100 g) were scheduled for SOP with TURARABrnational. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Perioperative endoscopic view of remnant adenomas (solid arrows).
Fig. 2. Perioperative endoscopic view of arterial bleeding in the prostatic fossa after
open suprapubic prostatectomy.
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previous transurethral surgery and conventional contraindications
to OP or prostate cancer on biopsy. All patients gave their informed
consent to the procedure. Prior to intervention, all patients were
analyzed using preoperative complete blood count, blood chemis-
try, International Prostate Symptom Scores (IPSS), transrectal ul-
trasound of the prostate and maximum urinary ﬂow rate (Qmax),
postvoid residual urine (PVRU) volume, digital rectal examination,
prostate speciﬁc antigen (PSA) measurement, and saturation (18
cores) TRUS-guided prostate biopsy if PSA was high (>4 ng/mL).
Postoperative outcome data were compared in the 1st month and
3rd month. All complications were recorded.
The patients were randomly subdivided into two groups. In
Group I, each patient underwent SOP. In Group II, each patient
underwent SOP with TURARAB.
2.2. Surgical technique
The procedure was performed under general anesthesia with
the patient in a low lithotomy position. A lower midline incision
was made from the umbilicus to the pubic symphysis. Vertical
cystotomy was performed using electrocautery. With the use of
electrocautery, cystotomy was extended cephalad and caudally to
within 1 cm of the prostate-vesical junction. A “ﬁgure-of-eight”
suture using a 2-0 Vicryl suture (ETHICON, Edinburgh, UK) was
placed and tied at the most caudal position of the cystostomy to
prevent further extension of the cystostomy incision. The bladder
neck and prostate gland were well visualized. After marking the
prostate, electrocautery created a circular incision in the mucosa of
the prostate-vesical junction distal to the trigone starting from the
posterior portion of the bladder neck to anterior portion. The plane
between the prostatic adenoma and prostatic capsule was devel-
oped by index ﬁnger dissection. Prostatic adenoma, either as one
unit or separate lobes, was removed from the prostatic fossa.
In Group I, hemostatic techniques in the prostatic fossa were per-
formed.3 Brieﬂy, discrete bleeding sites were controlled with elec-
trocautery or 4-0 chromic suture (ETHICON, Edinburgh, UK) ligatures.
In addition, a 0-chromic suturewasused toplace two “ﬁgure-of-eight”
shaped sutures to advance the bladdermucosa into the prostatic fossa
at the 5-o'clock and 7 o'clock positions at the prostate-vesical junction
to ensure control of the main arterial supply to the prostate.
In Group II, four stitches at the 12 o'clock, 3 o'clock, 6 o'clock, and 9
o'clockpositions by2-0Vicryl sutures (ETHICON, Edinburgh,UK)were
used to mark the limitation between the bladder neck and prostatic
fossa on TURRABC. To perform transurethral surgery for the residual
adenoma and remnant ﬁbrotic tissue (Fig. 1) and the severe bleeding
points (Fig. 2), the cystostomy site was clamped with several Babcock
clampers to prevent a leak of irrigation ﬂuid from the cystostomy
site. Any leakage of irrigation ﬂuidwas removed by suction tube. After
transurethral surgery, the prostatic fossa and external sphincter
were evaluated (Fig. 3). The cystotomy incision and skin were closed.
2.3. Statistical analysis
Baseline characteristics, perioperative data, Qmax, and PVRU of
the two groups were compared by ManneWhitney U test. A P
value ¼ 0.05 was considered signiﬁcant. Operation time was
measured from skin incision to skin closure.
3. Results
3.1. Baseline characteristics
There were no statistically signiﬁcant differences in baseline
characteristics between the two groups (Table 1).3.2. Perioperative results
There was a marked decrease in operation time and perioper-
ative bleeding in Group II compared with Group I (Table 1). Blood
transfusion during the operation was not needed in Group II due to
the easy control of arterial bleeding sites under the transurethral
procedure. In Group II, the mean time for TURARAB was 23.5 min.
3.3. Outcome of voiding functions
Postoperative voiding function was improved signiﬁcantly in all
groups (Table 2).
3.4. Complications
In Group I, blood transfusions were given to ﬁve patients due to
severe bleeding. Three patients received recatheterisation due to
clot retention. Wound dehiscence was seen in four patients. In
Fig. 3. Perioperative endoscopic view of apical prostatic urethra after removal and
trim of remnant adenoma by transurethral resection and cauterization.
Table 2
Improvement of voiding function of the groups.
Preoperative Postoperative P
(Mo 1) (Mo 3)
Group Ia)
Qmax 7.5 ± 3.5 23.1 ± 7.5 24.3 ± 3.7 <0.001
PVRU volume 251 ± 90.9 50.2 ± 25.6 20.4 ± 12.6 <0.001
IPSS 20.1 ± 5.0 14.3 ± 4.5 13.2 ± 3.4 0.037
Group IIb)
Qmax 6.1 ± 2.2 23.8 ± 12.7 25.3 ± 9.5 <0.001
PVRU volume 245 ± 120.6 32.6 ± 13.4 21.2 ± 12.3 <0.001
IPSS 19.2 ± 3.7 15.6 ± 5.2 11.5 ± 3.3 0.021
IPSS, International Prostate Symptom Score; PVRU, postvoid residual urine; Qmax,
maximum urinary ﬂow rate.
a) Group I, suprapubic open prostatectomy.
b) Group II, suprapubic prostatectomy followed by transurethral adjustment of
residual adenoma and bleeding.
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Wound dehiscence was present in one patient.
4. Discussion
Even though themortality of OP has decreased to a minimum,3,4
mainly owing to the advent of better preoperative evaluation and
anesthesia, with the therapeutic results obtained being excellent,
OP has been displaced by transurethral resection of the prostate
(TURP), mainly because of its invasiveness. However, despite
considerable blood loss and a prolonged recovery, OP has been the
traditional treatment of choice for extremely large prostates, over
100 g.5 In TURP, a larger prostate requires more resection time and
has been associated with increased blood loss. Enucleating a large
prostate can be much faster than removing it transurethrally.
Compared with TURP, OP offers the advantages of lower retreat-
ment rate and a more complete removal of the prostatic adenoma
under direct vision. However, basic OP requires ligations of both the
prostatic branch of the internal common iliac artery at the prostate-
vesical junction and the intraprostatic capsular arterial braches. TheTable 1
Preoperative and perioperative characteristics of the groups.
Group I
(n ¼ 29)a)
Group II
(n ¼ 20)b)
P
Age (y) 73.1 ± 5.2 72.1 ± 4.2 0.359
Total prostate volume (cc) 128.6 ± 17.4 125.1 ± 11.8 0.645
Preoperative IPSS 20.1 ± 5.0 19.2 ± 3.7 0.724
Preoperative PSA 14.9 ± 7.2 13.5 ± 6.7 0.154
Preoperative Qmax (mL/s) 7.5 ± 3.2 6.1 ± 2.2 0.635
Preoperative PVR volume 251 ± 90.9 245 ± 120.6 0.823
Resected tissue (mL) 85.2 ± 12.7 83.5 ± 23.5 0.072
Operative time (min) 123.1 ± 24.5 95.7 ± 14.9 0.015
Hospitalization (d) 12.1 ± 2.4 7.2 ± 1.2 0.032
Intraoperative transfusion rate (%) 12.5 0 0.020
Intraoperative loss of Hb (gm/dL) 3.3 ± 1.2 2.1 ± 0.9 0.043
IPSS, International Prostate Symptom Score; PSA, prostate speciﬁc antigen;
PVR, postvoid residual urine; Qmax, maximum urinary ﬂow rate.
a) Group I, suprapubic open prostatectomy.
b) Group II, suprapubic prostatectomy followed by transurethral adjust-
ment of residual adenoma and bleeding.ligations of intraprostatic capsular branches were very difﬁcult and
time consuming procedures because massive bleeding interrupts
the process of ﬁnding the bleeding points. This is the main cause of
blood loss and sometimes necessitates a blood transfusion. In
addition, when excessive bleeding persists after traction of the
ballooned urethral catheter, a cystoscopic inspection and fulgura-
tion of the prostatic fossa and bladder neck, or open reexploration
should be considered.
Since 1994, holmium laser enucleation of the prostate (HoLEP)
has been available for large prostates, but it is not easy to learn,
requires morcellation, requires a prolonged operation time, and
requires an expensive laser machine.6,7 Compared with HoLEP, SOP
with TURARAB also has an advantage of a reduced operating time.
Moody and Lingeman8 reported their HoLEP experience. Mean
preoperative prostate volume exceeded 100 g, and the operation
time was 197 min. Morcellation consisted of approximately one-
third of the total operating time (average 56/173 total operative
minutes). Compared with our data, SOP with TURARAB has the
advantage of a reduced operation time than HoLEP. Bipolar TURP
has been recently introduced as a minimal invasive surgical
method in the treatment of BPH. Coskuner et al.9 reported their
experience for large prostates (>100 g) with bipolar TURP. To the
best of our knowledge, their study is known to be unprecedented
for large prostates (>100 g) with bipolar TURP. Mean preoperative
prostate volume exceeded 116 g, and the operation time was
102 min. Compared with our data, operation time had no big dif-
ference. However, perioperative blood transfusion rate was 8.6% in
bipolar TURP. SOP with TURARAB has the advantage of reduced
perioperative blood transfusion rate than bipolar TURP. SOP with
TURARAB has an advantage of reduced operation time and bleeding
for patients with large prostates. But, an incision scar on the lower
abdomen is a disadvantage of our novel method compared with
HoLEP or bipolar TURP.
With the threshold for transfusion being a hemoglobin value of
10 g/dL, a transfusion rate of 8.2%was reported in a large study from
Italy.10 In our study, in Group I, the transfusion rate was 12.5%. To
reduce this kind of disadvantage of OP, we designed a novel SOP
with TURARAB. After removal of the main adenoma, we converted
the SOP to transurethral surgery. In this method, we were able to
ascertain the exact sites of bleeding foci, remnant adenoma, and
ﬁbrotic tissue (Figs. 1 and 2). This reduced bleeding during the
operation and perioperative hemorrhage, leading to a shortened
operation time.
In the classic SOP, the prostatic fossa must be examined for
discrete bleeding sites that can frequently be controlled with an
electrocautery or 4-0 chromic suture ligatures. In addition, two
“ﬁgure-of-eight” sutures of a 0-chromic are placed at the prosta-
tovesical junction to prevent severe bleeding from themain arterial
Y.S. Shin et al. / Prostate International 3 (2015) 31e3434blood supplies after removing the prostate adenoma. SOP with
TURARAB can save time in suturing bleeding sites. In our study, we
appreciably reduced the time for bleeding control compared with
SOP.
In addition, we were very surprised when we found many
ﬁbrotic tissues and remnant adenoma of the BPH at the enucleation
site, especially the apical area of the prostatic fossa. TURARAB has
advantages of being able to remove residual ﬁbrotic tissue and
remnant adenoma of BPH, to control severe bleeding and to create a
good shape of the prostatic urethra (Fig. 3). In our study, improved
voiding functionwas evident in both groups. But, long-term follow-
up of these two groups may yield a different outcome.
To perform TURARAB, the cystostomy site was clamped with
several Babcock clampers. The bladder was ﬁlled with Urosol, to
provide a clear view of the prostatic urethra from the bladder neck.
However, excessive pressure is exerted on the OP site of the pros-
tatic urethra, which may cause transurethral resection syndrome.
In our study, there was no case of transurethral resection syndrome
because we used continuous irrigation during the operation.
In conclusion, even for large prostate glands, SOPwith TURARAB
appears to be an effective and safe operation to reduce operation
time and bleeding for patients with large prostates who have to
undergo OP rather than endoscopic surgery.
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